

Genetic Analysis demonstrates global applicability of the GA-map® Dysbiosis Test in a peer-reviewed publication

OSLO, NORWAY – 16 July 2026: Genetic Analysis AS (“GA” or “the Company”) announces today the publication of a peer-reviewed study in the renowned scientific journal *Gut Microbes*. The publication demonstrates that the GA-map® Dysbiosis Test delivers consistent results across geographically diverse populations. These findings address one of the major challenges in microbiome diagnostics, population variability, and support the broader international applicability of the GA-map® diagnostic platform.

Demonstrating consistent diagnostic performance across different geographic regions is an important prerequisite for microbiome tests intended for widespread clinical use. The study, *“Towards Standardized Gut Microbiota Diagnostics: Normobiosis Beyond Geographical Borders,”* evaluates the performance of the GA-map® Dysbiosis Test across multiple international cohorts. Using its standardized, targeted marker panel and clinically validated interpretation algorithm, the test consistently classified microbiome status against a consistent healthy reference population across different geographic regions. These findings demonstrate how the GA-map® approach reduces analytical variability while maintaining diagnostic performance, supporting its integration into routine clinical settings and larger healthcare systems.

The first author of the publication, Pranvera Hiseni, Senior R&D Manager at GA, comments: *“Our strategy has always been to develop tests that transform complex microbiome signatures into clinically meaningful results. This study confirms that our approach performs consistently across geographical areas, opening the door to wider adoption by laboratories, healthcare providers, and partners globally.”*

The study analysed more than 800 samples from multiple countries and showed that the Dysbiosis Index (DI), the core output of the test, remains stable across populations. Importantly, healthy individuals from different regions exhibited comparable DI profiles, with no systematic geographic bias in dysbiosis classification.

Read the full publication here: [Full article: Towards standardized gut microbiota diagnostics: normobiosis beyond geographical borders](#)

Ronny Hermansen, CEO of Genetic Analysis, comments:

“The results of this publication reflect more than a decade of work to establish clinically meaningful and standardized microbiome diagnostics. It reinforces the strength of our technology and its readiness for broader international deployment. We are demonstrating that our microbiome diagnostics can move beyond research settings and become a reliable, scalable component of clinical practice.”

For more information, please contact:

Ronny Hermansen, CEO

E-mail: rh@genetic-analysis.com

About Genetic Analysis

Genetic Analysis AS (GA) is a molecular diagnostics company focused on developing targeted microbiome-based solutions using its proprietary GA-map® platform. With more than 15 years of experience in microbiome research and product development, the company works across disease areas including IBS, IBD, and recurrent *Clostridioides difficile* infection. GA-map® enables standardized and reproducible profiling of clinically relevant microbial patterns, supporting both research and diagnostic applications. GA employs a team of highly qualified employees with scientific backgrounds and competence in sales, operations, bioinformatics, molecular biology, and bioengineering.

For more information: www.genetic-analysis.com